Breast cancer generally occurs when breast cells grow uncontrollably. Mostly, breast cancer development starts in the duct that carries milk to the nipples.
Download the free sample copy of report @ https://www.pharmaproff.com/request-sample/1114
Some breast cancer cells develop in milk producing glands. As per the National Institutes of Health (NIH), in the U.S., 14.6% of all new cancer cases diagnosed every year are of breast cancer. Also, as per the American Cancer Society (ACS), 1 in every 5 woman has cancer cell in their breast tumour with several growth promoting protein receptors on their surface.
HER2 (human epidermal growth factor receptor 2) gene plays significant role in the development of breast cancer in most of the cases. Alpelisib is one of the key pipeline drug candidates for hormone sensitive breast cancer pipeline. Pfizer Inc., and Novartis AG are major players involved in the development of drugs for hormone sensitive breast cancer.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
- Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.
About Us:
Pharma Proff, a brainchild of Prescient & Strategic (P&S) Intelligence Private Limited, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.
We, at Pharma Proff, offer comprehensive reports in addition to providing pragmatic consultancy solutions to help our clients develop business strategies—critical to operations, R&D, product commercialization, and collaborations—that warrant enduring and sustainable results.
On the cusp of a new era that celebrates and lives by technology and holds immense potential for growth in the healthcare and pharmaceutical segments, we ensure our clients remain abreast of the changing industry landscape, comprehend the market dynamics analytically, and channelize their resources efficiently to maintain their stronghold in the market.
